Published

Avirmax Biopharma Announces First Patient Dosed in Clinical Trial of ABI-110, a Groundbreaking Gene Therapy for Wet AMD Including PCV

Summary by The Chandler Arizonan
HAYWARD, Calif., Nov. 21, 2024 /PRNewswire/ -- Avirmax Biopharma, Inc., a leader in the development of innovative gene therapies, today announced that the first patient has been successfully dosed in the Phase I/IIa clinical trial of ABI-110, the company's first…
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics